The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...
New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk's OZEMPIC Approval Heat Up the Chronic Kidney disease Therapeutic market | DelveInsight The FDA's recent approval of OZEMPIC ...
After its potential kidney disease drug went down in flames late last year, Novo Nordisk is pinning the blame on alleged ...
A lawsuit filed in the Singapore International Commercial Court is seeking $830 million in damages from KBP, with Novo ...
Additionally, Novo Nordisk is exploring expanded indications for its existing products. One notable development is the recent FDA approval of Ozempic for chronic kidney disease (CKD) patients with ...
In this regard Novo Nordisk is leading the way. We've become increasingly committed to chronic conditions that include cardiovascular disease and chronic kidney disease – the reason being ...
Novo Nordisk alleges Singaporean biotech KBP ... regional rights to roxadustat After ditching FibroGen’s chronic kidney disease drug roxadustat in the U.S., AstraZeneca has decided to take ...